Associations of Pre-Diagnostic Serum Levels of Total Bilirubin and Albumin With Lung Cancer Risk: Results From the Southern Community Cohort Study

Hyung-Suk Yoon, Xiao-Ou Shu, Chris Shidal, Jie Wu, William J. Blot, Wei Zheng and Qiuyin Cai*

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, United States

Background: Previous studies conducted among European and Asian decedents reported inverse associations of serum total bilirubin and albumin with lung cancer risk. Yet, no study has been conducted among African Americans or low-income European Americans.

Methods: This study included 522 incident lung cancer cases and 979 matched controls nested in the Southern Community Cohort Study, a cohort of predominantly low-income African and European Americans. Serum levels of total bilirubin and albumin, collected up to 11 years prior to case diagnoses, were measured by a clinical chemistry analyzer. Conditional logistic regression models were applied to evaluate the associations of total bilirubin and albumin with lung cancer risk.

Results: Overall, serum levels of total bilirubin (OR13 vs. T1 = 0.96, 95% CI: 0.66-1.39) were not significantly associated with lung cancer risk. However, higher levels of serum total bilirubin were significantly associated with decreased risk of lung cancer among participants who were diagnosed within two years following sample collection (OR13 vs. T1 = 0.36, 95% CI: 0.15-0.87) and among former/never smokers (OR13 vs. T1 = 0.54, 95% CI: 0.32-0.93). Serum levels of albumin were significantly associated with decreased risk of lung cancer overall (OR13 vs. T1 = 0.70, 95% CI: 0.50-0.98) and among African Americans (OR13 vs. T1 = 0.62, 95% CI: 0.41-0.96), but not among European Americans.

Conclusion: Our results indicate that in a low-income African American and European American population, serum levels of total bilirubin may be related to lung cancer progression and differ by smoking status. Meanwhile, the association of serum albumin levels with lung cancer risk may differ by race. Further studies are warranted to confirm these results.

Keywords: lung cancer, total bilirubin (TB), albumin (ALB), smoking, Southern Community Cohort Study low-income populations, African Americans
INTRODUCTION

Lung cancer is the third most common type of cancer, and its incidence varies by race/ethnicity and geographical location (1, 2). Cigarette smoking is the primary risk factor for lung cancer, but the mechanisms of lung carcinogenesis are still not well understood (3).

Antioxidants are free radical scavengers that can prevent damage from excessive reactive oxygen species (4) and may act as protective factors in carcinogenic progress (5). Bilirubin and albumin have attracted increasing attention due to their potent antioxidant properties, which may help prevent cancer by reducing inflammation and tumor cell proliferation (6–10). Bilirubin is produced as a byproduct of heme degradation and mostly transported in blood tightly bound to albumin, but a very small fraction of bilirubin remains unbound, i.e., free bilirubin, which has biological effects (11, 12). Several prospective studies investigating the associations of total bilirubin and albumin levels with lung cancer risk have been conducted (13–16), and a meta-analysis indicated an inverse association between total bilirubin levels and risk of lung cancer (17). However, this epidemiological evidence came mainly from studies conducted among European and Asian descendants. No study has been conducted among African Americans or socioeconomically disadvantaged populations who were experiencing elevated lung cancer rates (18).

In this study, we investigated the associations of pre-diagnostic serum levels of total bilirubin and albumin with lung cancer risk in the Southern Community Cohort Study (SCCS), a cohort study comprised of a large proportion of low-income African and European Americans. We further investigated whether the associations were modified by race, smoking status, and histological subtype.

METHODS

Study Population

The SCCS is a prospective cohort study designed to investigate the underlying causes of racial disparities in health outcomes. Detailed information on the SCCS is described in previous literature (19, 20). All study participants signed written informed consent before enrollment into the SCCS. Approximately 86% of the participants were recruited at community health centers (CHCs) that provide primary health care services for the primarily low-income and uninsured population. Trained interviewers conducted computer-assisted personal interviews to collect baseline data on demographic characteristics and potential health risk factors, including medical history, dietary habits, physical activity, smoking, alcohol consumption, and anthropometrics. Blood samples were collected for nearly half of CHC-enrolled participants and stored at our Vanderbilt freezer facilities.

A total of 522 incident lung cancer cases (defined by the International Classification of Diseases, 10th Revision: ICD-10, C340–C349) with stored blood specimens were ascertained via linkage with state cancer registries operating in the 12-state study area and/or from the National Death Index mortality records, by November 2016, and included in the current study. Controls (N=979) with stored blood samples were randomly selected from cancer-free SCCS participants and individually matched to cases at a 2:1 or 1:1 ratio on age (± 2 years), race (African American or European American), and sex, as well as the date (± 6 months) and site (CHC) of study enrollment, and thus, the date of blood collection. Completely de-identified data were available for the current analysis.

Laboratory Assays

Blood samples were provided by SCCS participants during enrollment at CHCs. After a blood draw, samples were immediately refrigerated and shipped cold overnight to the Vanderbilt Epidemiology Center’s Molecular Epidemiology Laboratory. Serum samples were isolated and stored at -80°C. An aliquot of serum samples was sent to the testing lab in dry ice for biomarker analyses. For samples included in the current study, comprehensive metabolic panels, including total bilirubin and albumin levels, were measured using the Beckman Coulter clinical chemistry analyzer (DXC 600) at the core research laboratory of the University of Washington’s Kidney Research Institute. Quality control samples (3%) were included in the assays. The intra- and inter-assay coefficients of variation were 0.9% and 1.9%, respectively, for albumin; and 12.7% and 13.4%, respectively, for total bilirubin. Serum samples from each case-control set were analyzed in the same batch and adjacent to eliminate between-assay variability. The laboratory staff was blinded to the case-control status of serum samples and the identity of quality control samples included in the study.

Statistical Analysis

This study included 522 lung cancer incident cases and 979 matched controls, which consisted of African Americans (334 lung cancer cases and 629 matched controls) and European Americans (188 lung cancer cases and 350 matched controls). Baseline characteristics between lung cancer cases and matched controls were compared by the chi-squared test (for categorical variables) or the student t-test (for continuous variables). Serum levels of total bilirubin and albumin were categorized into race-sex specific tertiles among controls. We also categorized serum levels of total bilirubin and albumin into tertiles among all controls, and the results were similar to those using race-sex specific tertiles. Thus, we present results using race-sex specific tertiles among controls. In addition, we further calculated the total bilirubin/albumin ratio grouped into race-sex specific tertiles. For this procedure, total bilirubin (mg/dL) and albumin (g/dL) were converted to µmol/L. We conducted conditional logistic regression analyses to investigate the associations between tertiles of total bilirubin and albumin and lung cancer risk after adjusting for potential confounders, including baseline age, smoking status (current vs. former vs. never), pack-years (<30 vs. ≥30), alcohol consumption (heavy vs. moderate vs.

Abbreviation: SCCS, Southern Community Cohort Study.
nondrinker), education (less than 11 years vs. completed high school vs. vocational/technical school vs. university degree or higher), household income (<$15,000 vs. $15,000-$24,999 vs. ≥$25,000), self-report of ever having been diagnosed with chronic obstructive pulmonary disease (COPD; no vs. yes), and body mass index (BMI; ≥ 30 kg/m\(^2\) vs. 29.9-25.0 kg/m\(^2\) vs. <25 kg/m\(^2\)). Stratified analyses were performed to investigate modifications by race (African American vs. European American) and the time between sample collection and lung cancer diagnosis (≤2 years vs. >2 years). We further conducted stratified analyses by smoking status and lung cancer histological subtype (adenocarcinoma, squamous cell, and small cell lung cancer). Interactions were evaluated by the likelihood ratio test. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA), with \(p\)-values of less than 0.05 being considered statistically significant.

**RESULTS**

Baseline characteristics of the study population are presented in Table 1. Lung cancer cases had a higher proportion of current smoking (74.3%) and higher pack-years (30.5 pack-years) than matched controls (46.5% and 19.2 pack-years, respectively). Compared with controls, lung cancer cases were more likely to be less educated, earn less income, be alcohol drinkers, have lower BMI, and have a history of COPD (Table 1).

Odds ratios (ORs) for lung cancer risk associated with serum levels of total bilirubin and albumin are presented in Table 2 and Supplementary Figure 1. Overall, serum levels of total bilirubin (\(OR_{T3 vs. T1} = 0.96, 95\% CI: 0.66-1.39\)) were not significantly associated with the risk of lung cancer. When the analyses were conducted separately for African Americans and European Americans, we observed a marginally significant interaction between race and serum total bilirubin levels (\(p_{interaction}=0.05\)). Higher serum levels of albumin were significantly associated with decreased risk of lung cancer (\(OR_{T3 vs. T1} = 0.70, 95\% CI: 0.50-0.98\)). The inverse association remained significant among African Americans (\(OR_{T3 vs. T1} = 0.62, 95\% CI: 0.41-0.96\)) but not among European Americans (\(OR_{T3 vs. T1} = 0.73, 95\% CI: 0.41-1.31\)) (Table 2). We also evaluated the associations of lung cancer risk with the total bilirubin/albumin ratio, a surrogate measurement of free bilirubin. As shown in Supplementary Table 1, no significant

**TABLE 1 | Baseline characteristics of study population, SCCS.**

|                               | Cases (N = 522) | Controls (N = 979) | \(p\)-value\(^{†}\) |
|-------------------------------|----------------|-------------------|-------------------|
| **Age (mean ± SD)**           | 56.4 ± 9.0     | 56.3 ± 9.0        | 0.77              |
| **Race [N (%)]**              |                |                   |                   |
| African Americans             | 334 (64.0)     | 629 (64.2)        | 0.92              |
| European Americans            | 188 (36.0)     | 350 (35.8)        |                   |
| **Gender [N (%)]**            |                |                   |                   |
| Men                           | 289 (55.4)     | 540 (55.2)        | 0.94              |
| Women                         | 233 (44.6)     | 439 (44.8)        |                   |
| **Smoking Status [N (%)]**    |                |                   |                   |
| Current                       | 388 (74.3)     | 455 (46.5)        | < 0.01            |
| Former                        | 104 (19.9)     | 240 (24.5)        |                   |
| Never                         | 30 (5.7)       | 284 (29.0)        |                   |
| **Pack-years\(^a\) [median [IQR]]** | 30.5 (17.6-48.0) | 19.2 (10.0-36.0) | < 0.01            |
| **Alcohol consumption [N (%)]** |               |                   |                   |
| Heavy                         | 125 (24.0)     | 162 (16.5)        | < 0.01            |
| Moderate\(^b\)                | 185 (35.4)     | 341 (34.8)        |                   |
| Nondrinker                    | 212 (40.6)     | 476 (48.6)        |                   |
| **Education [N (%)]**         |                |                   |                   |
| Less than 11 years            | 247 (47.3)     | 388 (39.6)        | < 0.01            |
| Completed high school         | 173 (33.1)     | 345 (35.2)        |                   |
| Vocational/technical school   | 88 (16.9)      | 171 (17.5)        |                   |
| University degree or higher   | 14 (2.7)       | 75 (7.7)          |                   |
| **Household income [N (%)]**  |                |                   |                   |
| < $15,000                     | 377 (72.2)     | 624 (63.7)        | < 0.01            |
| $15,000 - $24,999             | 96 (18.4)      | 220 (22.5)        |                   |
| ≥ $25,000                     | 49 (9.4)       | 135 (13.8)        |                   |
| **Self-report of COPD\(^c\) [N (%)]** | 432 (82.8)     | 885 (90.4)        | < 0.01            |
| Yes                           | 90 (17.2)      | 94 (9.6)          |                   |
| No                            |                |                   |                   |
| **BMI [kg/m\(^2\), median [IQR]]** | 25.8 (22.3-30.0) | 28.2 (24.5-33.1) | < 0.01            |
| Total Bilirubin [mg/dL, mean (SD)] | 0.41 (0.22)    | 0.45 (0.32)       | < 0.01            |
| Albumin [g/dL, mean (SD)]     | 4.28 (0.37)    | 4.31 (0.36)       | 0.08              |

\(^{†}\)Estimated by the student t-test procedure for continuous variables and chi-square test for categorical variables.

\(^{a}\)Included former/current smoker.

\(^{b}\)Defined as > 0 but ≤ 2 drink/day for men or ≤ 1 drink/day for women.

\(^{c}\)Ever diagnosed with emphysema or chronic bronchitis.
associations were found between the total bilirubin/albumin ratio and lung cancer risk, regardless of race.

We conducted analyses stratified by the time between sample collection and lung cancer diagnosis. Higher serum total bilirubin levels were significantly associated with decreased risk of lung cancer among participants diagnosed ≤2 years after blood collection (ORT$_{T3}$ vs. T1 = 0.36, 95% CI: 0.15-0.87; $p$ trend=0.03) (Table 3). Higher albumin levels were also associated with decreased risk of lung cancer, although not significantly, among participants diagnosed ≤2 years after blood collection (ORT$_{T3}$ vs. T1 = 0.57, 95% CI: 0.27-1.18). No significant associations were observed in individuals who were diagnosed >2 years after blood collection for either total bilirubin or albumin (Table 3).

We further conducted analyses by smoking status. Serum total bilirubin levels were associated with decreased risk of lung cancer among former/never smokers (ORT$_{T3}$ vs. T1 = 0.54, 95% CI: 0.32-0.93) but not among current smokers (Table 4). The associations of serum albumin levels were similar between current smokers and former/never smokers. We found no significant differences across histological types (i.e., adenocarcinoma, squamous cell lung cancer, and small cell lung cancer; data not shown).

**DISCUSSION**

This study investigated the associations of serum levels of total bilirubin and albumin with lung cancer risk among low-income Americans. Overall, total bilirubin was not associated with lung cancer risk, but higher serum levels of total bilirubin were associated with decreased risk of lung cancer within two years of blood collection and among former/never smokers. In addition, we found that higher levels of albumin were significantly inversely associated with lung cancer risk overall and among African Americans.

Previous studies among European and Asian decedents indicated an inverse association between total bilirubin and lung cancer risk. Horsfall and colleagues reported that a 0.1 mg/dL increase in total bilirubin was associated with a 33% decrease in the risk of lung cancer among European Americans.

**TABLE 2 | Association of serum levels of total bilirubin and albumin with lung cancer risk.**

| Table 2 | Association of serum levels of total bilirubin and albumin with lung cancer risk. |
|---------|--------------------------------------------------|
| **Total Bilirubin (mg/dL)** | **Cases** | **Controls** | **OR (95%CI)$^a$** | **OR (95%CI)$^b$** |
| **Total population** | N=522 | N=979 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 0.20 | 162 | 287 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 0.38 | 165 | 234 | 1.16 (0.82-1.63) | 1.09 (0.76-1.56) |
| T3 | 0.60 | 195 | 398 | 1.07 (0.75-1.52) | 0.96 (0.66-1.39) |
| $p$ trend | | | | 0.85 | 0.71 |
| **African Americans** | N=334 | N=629 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 0.20 | 91 | 179 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 0.37 | 128 | 214 | 1.48 (0.98-2.24) | 1.49 (0.95-2.33) |
| T3 | 0.60 | 115 | 236 | 1.35 (0.86-2.12) | 1.22 (0.75-1.98) |
| $p$ trend | | | | 0.28 | 0.61 |
| **European Americans** | N=188 | N=350 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 0.20 | 71 | 108 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 0.40 | 37 | 80 | 0.63 (0.33-1.21) | 0.52 (0.26-1.04) |
| T3 | 0.60 | 80 | 162 | 0.86 (0.36-2.12) | 0.87 (0.30-2.10) |
| $p$ trend | | | | 0.25 | 0.15 |
| **Albumin (g/dL)** | **Cases** | **Controls** | **OR (95%CI)$^a$** | **OR (95%CI)$^b$** |
| **Total population** | N=522 | N=979 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 3.90 | 173 | 283 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 4.30 | 178 | 339 | 0.86 (0.62-1.18) | 0.88 (0.63-1.23) |
| T3 | 4.60 | 171 | 357 | 0.78 (0.56-1.07) | 0.70 (0.50-0.98) |
| $p$ trend | | | | 0.12 | 0.04 |
| **African Americans** | N=334 | N=629 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 3.90 | 115 | 185 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 4.30 | 114 | 221 | 0.83 (0.56-1.23) | 0.90 (0.60-1.37) |
| T3 | 4.60 | 105 | 223 | 0.72 (0.49-1.08) | 0.62 (0.41-0.96) |
| $p$ trend | | | | 0.11 | 0.03 |
| **European Americans** | N=188 | N=350 | 1.00 (Ref.) | 1.00 (Ref.) |
| T1 | 4.00 | 58 | 98 | 1.00 (Ref.) | 1.00 (Ref.) |
| T2 | 4.30 | 64 | 118 | 0.89 (0.50-1.55) | 0.87 (0.45-1.56) |
| T3 | 4.70 | 66 | 134 | 0.85 (0.49-1.45) | 0.73 (0.41-1.31) |
| $p$ trend | | | | 0.55 | 0.28 |
| **$p$ interaction**$^c$ | | | | 0.89 | 0.79 |

Analysis using conditional logistic regression models.

$^a$Median level of each tertile.

$^b$Based on the race- and sex-specific tertiles among controls.

$^c$p interaction between Total Bilirubin/Albumin and race with lung cancer risk.

$^d$Adjustment for age, smoking status, pack-years.

$^e$Adjustment for age, smoking status, pack-years, alcohol consumption, education, household income, history of COPD, and BMI.
A decrease in serum bilirubin levels was associated with a lower risk of lung cancer in both men [incidence rate ratio (IRR)=0.92, 95% CI: 0.89-0.95] and women (IRR=0.89, 95% CI: 0.86-0.93) (9). In the EPIC-Heidelberg cohort study, higher levels of bilirubin showed a marginally significant association with a lower risk of lung cancer [hazard ratio (HR)=0.72, 95% CI: 0.51-1.00]. Wen and colleagues reported that bilirubin was inversely associated with lung cancer risk and mortality in Taiwanese male smokers (14). The Severance Cohort Study in Korea reported an increased risk of lung cancer with bilirubin levels from 0.2 to 0.7 mg/dL in men (HR=2.8, 95% CI: 1.8-4.2), compared with bilirubin levels ≥1.0 mg/dL (15). The authors also observed that one standard deviation (SD) increase in bilirubin was associated with a 30% decreased risk of lung cancer (HR=0.7, 95% CI: 0.5-0.9) among current smokers. A Japanese study using electronic medical records during a median 4.7-year follow-up demonstrated that serum bilirubin levels over 1.2 mg/dL were associated with a reduced risk of lung cancer among men (HR=0.47, 95% CI: 0.27-0.83) compared with ≤1.2 mg/dL (10). A large-scale study from Sweden also reported an inverse association between serum total bilirubin levels and lung cancer risk in men and women (HR=0.85, 95% CI: 0.80-0.91) (9).

### Table 3: Association of serum levels of total bilirubin and albumin with lung cancer risk by time between blood collection and lung cancer diagnosis.

|                  | Median* (Cases N=128) | Controls N=234 | OR (95%CI)† | OR (95%CI)‡ |
|------------------|------------------------|----------------|-------------|-------------|
| ≤ 2 years        |                        |                |             |             |
| Total Bilirubin (mg/dL)b | 0.20 (70) | 106 | 1.00 (Ref.) | 1.00 (Ref.) |
|                  | 0.37 (34) | 64 | 0.87 (0.44-1.72) | 0.80 (0.38-1.67) |
|                  | 0.60 (24) | 64 | 0.50 (0.23-1.06) | 0.36 (0.15-0.87) |
|                  | p trend    | 0.07 | 0.36 | 0.03 |
| Albumin (g/dL)b  | 4.00 (30) | 52 | 1.00 (Ref.) | 1.00 (Ref.) |
|                  | 4.30 (55) | 77 | 0.80 (0.38-1.67) | 0.70 (0.32-1.52) |
|                  | 4.60 (43) | 105 | 0.60 (0.30-1.20) | 0.57 (0.27-1.16) |
|                  | p trend    | 0.14 | 0.14 | 0.05 |
| > 2 years        |                        |                |             |             |
| Total Bilirubin (mg/dL)b | 0.20 (92) | 181 | 1.00 (Ref.) | 1.00 (Ref.) |
|                  | 0.40 (131) | 230 | 1.35 (0.90-2.04) | 1.25 (0.81-1.94) |
|                  | 0.60 (171) | 334 | 1.36 (0.89-2.07) | 1.17 (0.75-1.83) |
|                  | p trend    | 0.22 | 0.84 | 0.64 |
| Albumin (g/dL)b  | 3.90 (143) | 231 | 1.00 (Ref.) | 1.00 (Ref.) |
|                  | 4.30 (123) | 262 | 0.86 (0.60-1.22) | 0.88 (0.60-1.28) |
|                  | 4.60 (128) | 252 | 0.84 (0.58-1.20) | 0.74 (0.50-1.09) |
|                  | p trend    | 0.35 | 0.12 | 0.20 |

Analysis using conditional logistic regression model.
*Median level of each tertile.
bBased on the race- and sex-specific tertiles among controls.
†Adjustment for age, smoking status, and pack-years.
‡Adjustment for age, smoking status, pack-years, alcohol consumption, education, household income, history of COPD, and BMI.

### Table 4: Association of serum levels of total bilirubin and albumin with lung cancer risk by smoking status.

|                  | Current Smokers (N=388) | Controls (N=455) | OR (95%CI)† |
|------------------|------------------------|-----------------|-------------|
| Total Bilirubin (mg/dL)b | 0.20 (117) | 143 | 1.00 (Ref.) |
|                  | 0.39 (118) | 137 | 1.06 (0.73-1.54) |
|                  | 0.60 (153) | 175 | 1.03 (0.73-1.45) |
|                  | p trend    | 0.87 | 0.03 |
| Albumin (g/dL)b  | 3.90 (128) | 137 | 1.00 (Ref.) |
|                  | 4.30 (128) | 154 | 0.94 (0.66-1.34) |
|                  | 4.60 (132) | 164 | 0.83 (0.58-1.17) |
|                  | p trend    | 0.28 | 0.20 |

|                  | Former and Never Smokers (N=134) | Controls (N=524) | OR (95%CI)† |
|------------------|----------------------------------|-----------------|-------------|
| Total Bilirubin (mg/dL)b | 0.20 (45) | 144 | 1.00 (Ref.) |
|                  | 0.37 (47) | 157 | 0.90 (0.54-1.51) |
|                  | 0.60 (42) | 223 | 0.54 (0.32-0.93) |
|                  | p interaction: 0.19 | 0.00 | 0.05 |
| Albumin (g/dL)b  | 4.00 (45) | 146 | 1.00 (Ref.) |
|                  | 4.30 (50) | 185 | 1.03 (0.61-1.72) |
|                  | 4.60 (39) | 193 | 0.70 (0.40-1.22) |
|                  | p interaction: 0.60 | 0.22 | 0.22 |

*Median level of each tertile.
bBased on the race- and sex-specific tertiles among controls.
†Adjustment for age, sex, race, smoking status, pack-years, alcohol consumption, education, household income, history of COPD, and BMI.
Bilirubin and lung cancer risk ($HR_{Q4\text{ vs.} Q1} = 0.50, 95\% \text{ CI:} 0.44\text{-}0.59$) (17): this study showed that higher serum total bilirubin levels decreased the risk of lung cancer among non-smokers ($HR=0.45, 95\% \text{ CI:} 0.24\text{-}0.86$) but not among smokers ($HR=0.84, 95\% \text{ CI:} 0.44\text{-}1.60$). In addition, a meta-analysis of five cohort studies reported that high levels of bilirubin were associated with decreased risk of lung cancer (relative risk$=0.69, 95\% \text{ CI:} 0.55\text{-}0.86$) (17). A study from the UK Biobank reported a potential causal association between serum bilirubin and the incidence of lung cancer by Mendelian Randomization (21); this study suggested that genetically predicted serum bilirubin might protect individuals from exposure hazards to high levels of oxidants associated with cigarette smoking. Unlike previous studies, our study did not find a significant association between total bilirubin levels and lung cancer risk among total study participants. It is worth noting that our study was conducted among low-income African Americans and European Americans. Nevertheless, we found an inverse association of total bilirubin levels with lung cancer risk among cases diagnosed within two years after blood collection. This suggests that total bilirubin may be related to lung cancer progression and could potentially be a lung cancer biomarker. In addition, the inverse association of serum total bilirubin levels was only observed among former/never smokers in our study, indicating that total bilirubin may be a promising biomarker for non-current smokers.

Bilirubin exhibits potent antioxidant effects and has been shown to reduce age-related inflammation and metabolic deterioration in preclinical rodent models (22). The link between inflammation and cancer has long been recognized. Thus, endogenous compounds reducing inflammation have been generally hypothesized to have cancer-preventive properties. Additional mechanisms also indicate a protective role of bilirubin in cancer risk: bilirubin may act as an immunomodulatory agent and has been shown to suppress CD4 T cell responses (23). CD4-positive T cells, along with their related cytokines, are associated with lung cancer risk (24).

We found that higher albumin levels were associated with decreased risk of lung cancer overall and among African Americans. A previous study reported that higher levels of albumin had a marginally significant association with a lower risk of lung cancer ($HR=0.72, 95\% \text{ CI:} 0.51\text{-}1.00$) (13). Recently, the Kailuan cohort in China showed that pre-diagnostic albumin was inversely associated with lung cancer risk ($HR_{Q4\text{ vs.} Q1} = 0.70, 95\% \text{ CI:} 0.52\text{-}0.95$), but the inverse association became insignificant after excluding cases diagnosed within two years of enrollment (25). Another study also reported that one SD increment in albumin was inversely associated with lung cancer risk ($HR=0.82, 95\% \text{ CI:} 0.72\text{-}0.94$) among Koreans (26).

Albumin plays a role as a scavenger and antioxidant (8, 27–29), which may reflect the inflammatory and nutritional status (30). Albumin can be broken down in the cell, but it still provides amino acids for cell proliferation and matrix deposition (28). Low serum albumin levels are generally regarded as an indicator of severe inflammation or malnutrition (28, 31). The inverse correlations of serum albumin levels with C-reactive protein and tumor necrosis factor-α also support the association between serum albumin and inflammation (32–34). Given a strong link of chronic infection and inflammatory microenvironment to lung cancer (35), the inverse associations of serum albumin that we observed in the current study could be biologically plausible. However, future investigations are needed to further explore the biological role of albumin in the development of lung cancer and whether the molecular mechanisms underneath the albumin-inflammation association differ by race/ethnicity or socio-economic status.

The current study has several strengths. First, we conducted a population-based nested case-control study, including African Americans and low-income populations in the US. This could provide a unique insight into the associations of serum total bilirubin and albumin with lung cancer among underserved populations who are at a greater risk for lung cancer. Second, our study used blood samples collected before lung cancer diagnosis and treatment, thus minimizing potential reverse causality. Finally, comprehensive covariate information from the SCCS allowed us to adjust for major confounders. The limitations of our study should also be noted. Larger sample size was necessary for additional stratified analyses by smoking status and lung cancer histological subtypes. Despite the comprehensive adjustments for covariates, we could not completely rule out the influence of residual confounding variables, unmeasured potential confounders, or one-time measurements.

CONCLUSION

Our findings show that total bilirubin serum levels were inversely associated with short-term lung cancer incidence, particularly within two years of blood collection. These findings raise the possibility that lung cancer itself and/or its immediate clinical precursors may influence (lower) total bilirubin levels, leading to the appearance of a protective effect of the biomarkers upon lung cancer. However, the absence of associations beyond two years may imply that serum levels of total bilirubin are unrelated to lung cancer risk. In addition, total bilirubin was associated with decreased lung cancer risk among former/never smokers, indicating that total bilirubin may be a promising biomarker for non-current smokers. We also found that serum albumin was inversely associated with lung cancer risk overall and among African Americans. Further studies with a larger sample size are warranted to confirm our findings, especially on effect modification by race/ethnicity and smoking status.

DATA AVAILABILITY STATEMENT

Data used in the present study can be requested through the Southern Community Cohort Study online request system (https://ors.southerncommunitystudy.org/).
ETHICS STATEMENT

The SCCS protocol was reviewed and approved by the institutional review boards at Vanderbilt University Medical Center and Meharry Medical College. The participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

QC conceived of the study. WZ and WB provided study resources. QC and JW conducted laboratory analyses. HSY and CS performed statistical analyses. All authors contributed to interpretation of results. HSY, CS, XS, and QC drafted the manuscript. All authors approved the final version of the manuscript.

FUNDING

This work was supported by the National Institutes of Health (T32CA160056, R01CA092447, and U01CA202979). Data collection and sample preparation were performed by the Survey and Biospecimen Shared Resource which is supported in part by the Vanderbilt-Ingram Cancer Center (P30CA68485).

ACKNOWLEDGMENTS

Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, Little Rock, AR 72,205. The Arkansas Central Cancer Registry is fully funded by a grant from the National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The authors thank the study participants and research staff of the Southern Community Cohort Study for their contribution to this study. We also thank Regina Courtney for laboratory management and Dr. Mary Shannon Byers and Ms. Kathleen Harmeyer for editing and manuscript preparation.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71:7–33. doi: 10.3322/caac.21654
2. American Lung Association. Too Many Cases, Too Many Deaths. (Washington D.C: American Lung Association), (2010).
3. Ryan BM. Lung Cancer Health Disparities. Carcinogenesis (2018) 39:741–51. doi: 10.1093/carcin/bgy047
4. Pham-Huy LA, He H, Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. Int J BioMed Sci (2008) 4:89–96.
5. Marnett LJ. Oxyradicals and DNA Damage. Carcinogenesis (2000) 21:361–70. doi: 10.1093/carcin/21.3.361
6. Peng YF, Goyal H, Xu GD. Serum Bilirubin has an Important Role in Multiple Clinical Applications. J Lab Precis Med (2017) 2:82–2. doi: 10.21037/jlpm.2017.09.08
7. Gupta D, Lis CG. Pretreatment Serum Albumin as a Predictor of Cancer Survival: A Systematic Review of the Epidemiological Literature. Nutr J (2010) 9:69. doi: 10.1186/1475-2891-9-69
8. Roche M, Rondel P, Singh NR, Tarnus E, Bourdon E. The Antioxidant Properties of Serum Albumin. FEBS Lett (2008) 582:1783–7. doi: 10.1016/j.febslet.2008.04.057
9. Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, et al. Serum Bilirubin and Risk of Respiratory Disease and Death. JAMA (2011) 305:691–7. doi: 10.1001/jama.2011.124
10. Inoguchi T, Nohara Y, Nojiri C, Nakashima N. Association of Serum Bilirubin Levels With Risk of Cancer Development and Total Death. Sci Rep (2021) 11:13224. doi: 10.1038/s41598-021-92442-2
11. Dudeja V, Ferrantella A, Fong Y. The Liver. In: Sabiston Textbook of Surgery, 21st ed. Philadelphia, PA: Elsevier (2021).
12. Adin CA. Bilirubin as a Therapeutic Molecule: Challenges and Opportunities. Antioxidants (2021) 10:1536. doi: 10.3390/antiox1015136
13. Kühn T, Sookthai D, Graf ME, Schübel R, Freisling H, Johnson T, et al. Albumin, Bilirubin, Uric Acid and Cancer Risk: Results From a Prospective Population-Based Study. Br J Cancer (2017) 117:1572–9. doi: 10.1038/bjc.2017.313
14. Wen CP, Zhang F, Liang D, Wen C, Gu J, Skinner H, et al. The Ability of Bilirubin in Identifying Smokers With Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction With Global Metabolomic Profiling. Clin Cancer Res (2015) 21:193–200. doi: 10.1158/1078-0432.CCR-14-0748
15. Lim JE, Kimm H, Lee SH. Combined Effects of Smoking and Bilirubin Levels on the Risk of Lung Cancer in Korea: The Severance Cohort Study. PLoS One (2014) 9:e103972. doi: 10.1371/journal.pone.0103972

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.895479/full#supplementary-material

Supplementary Figure 1 | Association of serum levels of total bilirubin and albumin with lung cancer risk.

Supplementary Table 1 | Association of serum levels of total bilirubin/albumin ratio with lung cancer risk.
